Catalyst Dossier · compiled by CeliA 🧫

Galapagos NV (GLPG)

Biotechnology · market cap $1.9B · as of 2026-07-01

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Galapagos NV (GLPG) is a Belgian biotechnology company with 704 employees and a market cap of approximately $1.9B, trading near $28.81. Its lead asset, filgotinib, is in Phase 3 development for Crohn's Disease, supported by a broad Phase 2 pipeline spanning cystic fibrosis, rheumatoid arthritis, IPF, dermatomyositis, ulcerative colitis, systemic sclerosis, and osteoarthritis. The data picture is sparse: no upcoming catalysts are on the calendar, financials are not disclosed in the provided facts, and analyst coverage is minimal with a single target of $27.21.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
GLPG2737	Phase 2	Cystic Fibrosis
GLPG3667	Phase 2	Dermatomyositis
GLPG2222 50 mg	Phase 2	Cystic Fibrosis
GLPG1205	Phase 2	Idiopathic Pulmonary Fibrosis
Filgotinib	Phase 3	Crohn's Disease
GLPG3970	Phase 2	Rheumatoid Arthritis
GLPG1837 dose 1	Phase 2	Cystic Fibrosis
GLPG0974	Phase 2	Ulcerative Colitis
GLPG2222 150 mg q.d.	Phase 2	Cystic Fibrosis
GLPG1837 dose 2	Phase 2	Cystic Fibrosis
GLPG1690 600 mg QD	Phase 2	Idiopathic Pulmonary Fibrosis
GLPG0634	Phase 2	Rheumatoid Arthritis
GLPG1690	Phase 2	Systemic Sclerosis
GLPG1972	Phase 2	Osteoarthritis
GLPG0259 oral capsule	Phase 2	Rheumatoid Arthritis

Price & technical context

3-month

-16.8%

6-month

-7.0%

12-month

+6.1%

52-wk range

$25.07–$37.62

vs 50-day MA

-5.4%

vs 200-day MA

-10.4%

Realized vol

30.1%

Max drawdown

-27.1%

Daily closes through 2026-05-06. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for GLPG (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 15 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.